SanBio Co., Ltd

Japan has cautiously granted a conditional, global-first approval to SanBio Co., Ltd ’s autologous mesenchymal stem cell (MSC)-based therapy Akuugo (vandefitemcel; SB623) for traumatic brain injury (

The NOSTRA III study of Germany’s Vasopharm GmbH ’s inducible nitric oxide synthase inhibitor ronopterin (VAS203) has missed its primary endpoint in patients with traumatic brain injury (TBI), but th

While Takeda Pharmaceutical Co. Ltd. 's $62bn acquisition of Shire PLC was formally completed in the first week of 2019, the ramifications continued to be felt over the following 12 months, as the

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Roche Pays Rheos $42.5m Up F